Kite Pharma, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 22 rows in 2014. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2014-12-24: Reporting owner Wiezorek Jeffrey; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-12-24: Reporting owner Chang David D; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-12-24: Reporting owner BUTITTA CYNTHIA M; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2014-12-24: Reporting owner Belldegrun Arie; Form 4; Security Employee Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2014-12-24 | Wiezorek Jeffrey Officer (VP Clinical Development) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +16,100 16,100 owned after | $51.96 exercise price | 2014-12-30 | |
| 2014-12-24 | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $51.96 exercise price | 2014-12-30 | |
| 2014-12-24 | BUTITTA CYNTHIA M Officer (COO and CFO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +75,000 75,000 owned after | $51.96 exercise price | 2014-12-30 | |
| 2014-12-24 | Belldegrun Arie Director, Officer (Chairman, President and CEO), 10% Owner | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +139,200 139,200 owned after | $51.96 exercise price | 2014-12-30 | |
| 2014-06-27 holding as of filing | Ruchefsky Steven B Director | 3/A | Director Stock Option (Right to Buy) Derivative · Direct | Holding | $0.70 exercise price | 2014-06-27 | ||
| 2014-06-19 | Better Marc Officer (VP, Product Sciences) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $17.00 exercise price | 2014-06-23 | |
| 2014-06-19 | Roberts Margo R Officer (Chief Scientific Officer) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +50,000 50,000 owned after | $17.00 exercise price | 2014-06-23 | |
| 2014-06-19 | BUTITTA CYNTHIA M Officer (COO and CFO) | 4 | Employee Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +149,511 149,511 owned after | $17.00 exercise price | 2014-06-23 | |
| 2014-06-19 holding as of filing | Wiezorek Jeffrey Officer (VP Clinical Development) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $6.89 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | Sproule Rizwana F Officer (VP Regulatory Affairs) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | Ruchefsky Steven B Director | 3 | Director Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | Roberts Margo R Officer (Chief Scientific Officer) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.70 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | Peacock Jonathan M Director | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | Nussbaum Ran Director | 3 | Director Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | Kazam Joshua A Director | 3 | Director Stock Option (Right to Buy) Derivative · Direct | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | DOUMANI ROY Director | 3 | Director Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | DOUMANI ROY Director | 3 | Director Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $6.89 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | Chang David D Officer (EVP, R&D, Chief Medical Off.) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $6.89 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | CHAMPSI FARAH Director | 3 | Director Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | BUTITTA CYNTHIA M Officer (COO and CFO) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | BONDERMAN DAVID Director | 3 | Director Stock Option (Right to Buy) Derivative · Direct · (m) | Holding | $1.35 exercise price | 2014-06-19 | ||
| 2014-06-19 holding as of filing | Better Marc Officer (VP, Product Sciences) | 3 | Employee Stock Option (Right to Buy) Derivative · Direct | Holding | $0.38 exercise price | 2014-06-19 |